GRTSQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GRTSQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gritstone Bio's Revenue per Share for the three months ended in Jun. 2024 was $0.00.
During the past 12 months, Gritstone Bio's average Revenue per Share Growth Rate was -88.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was -49.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -26.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 8 years, the highest 3-Year average Revenue per Share Growth Rate of Gritstone Bio was 64.50% per year. The lowest was -49.30% per year. And the median was -7.80% per year.
For the Biotechnology subindustry, Gritstone Bio's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Gritstone Bio's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Gritstone Bio's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
Gritstone Bio (OTCPK:GRTSQ) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Thank you for viewing the detailed overview of Gritstone Bio's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew R Allen | director, officer: President and CEO | 2525 28TH STREET, SUITE 200, BOULDER CO 80301 |
Matthew Hawryluk | officer: See Remarks | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Erin Jones | officer: See Remarks | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Vassiliki Economides | officer: See Remarks | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Karin Jooss | officer: See Remarks | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Lawrence Corey | director | C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608 |
Naiyer Rizvi | director | C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Elaine V Jones | director | C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101 |
Clare Fisher | director | C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608 |
Steve E. Krognes | director | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Shefali Agarwal | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
James Cho | officer: Chief Accounting Officer | C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608 |
Raphael Rousseau | officer: See Remarks | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Roman Yelensky | officer: See Remarks | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Thomas Woiwode | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
From GuruFocus
By Marketwired • 08-05-2024
By Marketwired • 08-04-2024
By Marketwired • 07-30-2024
By PRNewswire • 08-05-2024
By Business Wire • 10-10-2024
By PRNewswire • 08-03-2024
By PRNewswire • 08-06-2024
By PRNewswire • 08-01-2024
By PRNewswire • 08-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.